Zacks.com on MSN2h
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic & Inflammatory Disease ...
2 Top Growth Stocks to Buy on the Dip
2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...
Skye Bioscience, Inc.: Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...
Taiwan News20h
Saudi Arabia Carbonates Market Growth, Trends, Consumer Preferences, and Competitive Landscape 2025-2033
Request To Download Free Sample of This Strategic Report @ The publisher has been closely monitoring the various markets in Saudi Arabia Carbonates Market. This report provides a comprehensive ...